Top

Published in:

01-09-2018

Role of autotaxin in cancer stem cells

Authors: Dongjun Lee, Dong-Soo Suh, Sue Chin Lee, Gabor J. Tigyi, Jae Ho Kim

Published in: Cancer and Metastasis Reviews | Issue 2-3/2018

Abstract

Stem cells are a rare subpopulation defined by the potential to self-renew and differentiate into specific cell types. A population of stem-like cells has been reported to possess the ability of self-renewal, invasion, metastasis, and engraftment of distant tissues. This unique cell subpopulation has been designated as cancer stem cells (CSC). CSC were first identified in leukemia, and the contributions of CSC to cancer progression have been reported in many different types of cancers. The cancer stem cell hypothesis attempts to explain tumor cell heterogeneity based on the existence of stem cell-like cells within solid tumors. The elimination of CSC is challenging for most human cancer types due to their heightened genetic instability and increased drug resistance. To combat these inherent abilities of CSC, multi-pronged strategies aimed at multiple aspects of CSC biology are increasingly being recognized as essential for a cure. One of the most challenging aspects of cancer biology is overcoming the chemotherapeutic resistance in CSC. Here, we provide an overview of autotaxin (ATX), lysophosphatidic acid (LPA), and their signaling pathways in CSC. Increasing evidence supports the role of ATX and LPA in cancer progression, metastasis, and therapeutic resistance. Several studies have demonstrated the ATX-LPA axis signaling in different cancers. This lipid mediator regulatory system is a novel potential therapeutic target in CSC. In this review, we summarize the evidence linking ATX-LPA signaling to CSC and its impact on cancer progression and metastasis. We also provide evidence for the efficacy of cancer therapy involving the pharmacological inhibition of this signaling pathway.

Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews. Cancer, 8(10), 755–768. https://doi.org/10.1038/nrc2499.PubMedCrossRef

Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Cacerescortes, J., et al. (1994). A cell initiating human acute myeloid-leukemia after transplantation into Scid mice. Nature, 367(6464), 645–648. https://doi.org/10.1038/367645a0.PubMedCrossRef

Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737. https://doi.org/10.1038/nm0797-730.PubMedCrossRef

Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.PubMed

Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 14(3), 275–291. https://doi.org/10.1016/j.stem.2014.02.006.PubMedCrossRef

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983–3988. https://doi.org/10.1073/pnas.0530291100.PubMedPubMedCentralCrossRef

Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65(23), 10946–10951. https://doi.org/10.1158/0008-5472.CAN-05-2018.PubMedCrossRef

Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3), 313–323. https://doi.org/10.1016/j.stem.2007.06.002.PubMedCrossRef

O'Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 106–110. https://doi.org/10.1038/nature05372.PubMedCrossRef

10.

Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, P., Weissman, I. L., Clarke, M. F., & Ailles, L. E. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104(3), 973–978. https://doi.org/10.1073/pnas.0610117104.PubMedPubMedCentralCrossRef

11.

Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 15(3), 504–514. https://doi.org/10.1038/sj.cdd.4402283.PubMedCrossRef

12.

Ishizawa, K., Rasheed, Z. A., Karisch, R., Wang, Q., Kowalski, J., Susky, E., Pereira, K., Karamboulas, C., Moghal, N., Rajeshkumar, N. V., Hidalgo, M., Tsao, M., Ailles, L., Waddell, T. K., Maitra, A., Neel, B. G., & Matsui, W. (2010). Tumor-initiating cells are rare in many human tumors. Cell Stem Cell, 7(3), 279–282. https://doi.org/10.1016/j.stem.2010.08.009.PubMedPubMedCentralCrossRef

13.

Beck, B., & Blanpain, C. (2013). Unravelling cancer stem cell potential. Nature Reviews. Cancer, 13(10), 727–738. https://doi.org/10.1038/nrc3597.PubMedCrossRef

14.

Morrison, R., Schleicher, S. M., Sun, Y., Niermann, K. J., Kim, S., Spratt, D. E., Chung, C. H., & Lu, B. (2011). Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. Journal of Oncology, 2011, 941876. https://doi.org/10.1155/2011/941876.PubMedCrossRef

15.

Wang, Y. H., Israelsen, W. J., Lee, D., Yu, V. W., Jeanson, N. T., Clish, C. B., et al. (2014). Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell, 158(6), 1309–1323. https://doi.org/10.1016/j.cell.2014.07.048.PubMedPubMedCentralCrossRef

16.

Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.PubMedCrossRef

17.

Wang, Y. H., & Scadden, D. T. (2015). Harnessing the apoptotic programs in cancer stem-like cells. EMBO Reports, 16(9), 1084–1098. https://doi.org/10.15252/embr.201439675.PubMedPubMedCentralCrossRef

18.

Janiszewska, M., Suva, M. L., Riggi, N., Houtkooper, R. H., Auwerx, J., Clement-Schatlo, V., Radovanovic, I., Rheinbay, E., Provero, P., & Stamenkovic, I. (2012). Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes & Development, 26(17), 1926–1944. https://doi.org/10.1101/gad.188292.112.CrossRef

19.

Alvero, A. B., Montagna, M. K., Holmberg, J. C., Craveiro, V., Brown, D., & Mor, G. (2011). Targeting the mitochondria activates two independent cell death pathways in ovarian Cancer stem cells. Molecular Cancer Therapeutics, 10(8), 1385–1393. https://doi.org/10.1158/1535-7163.Mct-11-0023.PubMedPubMedCentralCrossRef

20.

Leal, J. A., & Lleonart, M. E. (2013). MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Letters, 338(1), 174–183. https://doi.org/10.1016/j.canlet.2012.04.020.PubMedCrossRef

21.

Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., & Song, E. (2007). Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131(6), 1109–1123. https://doi.org/10.1016/j.cell.2007.10.054.PubMedCrossRef

22.

Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., & Jacks, T. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3903–3908. https://doi.org/10.1073/pnas.0712321105.PubMedPubMedCentralCrossRef

23.

Huynh, C., Segura, M. F., Gaziel-Sovran, A., Menendez, S., Darvishian, F., Chiriboga, L., Levin, B., Meruelo, D., Osman, I., Zavadil, J., Marcusson, E. G., & Hernando, E. (2011). Efficient in vivo microRNA targeting of liver metastasis. Oncogene, 30(12), 1481–1488. https://doi.org/10.1038/onc.2010.523.PubMedCrossRef

24.

Valdes-Rives, S. A., & Gonzalez-Arenas, A. (2017). Autotaxin-lysophosphatidic acid: from inflammation to Cancer development. Mediators of Inflammation, 2017, 9173090–9173015. https://doi.org/10.1155/2017/9173090.PubMedPubMedCentralCrossRef

25.

Mills, G. B., & Moolenaar, W. H. (2003). The emerging role of lysophosphatidic acid in cancer. Nature Reviews. Cancer, 3(8), 582–591. https://doi.org/10.1038/nrc1143.PubMedCrossRef

26.

van Meeteren, L. A., & Moolenaar, W. H. (2007). Regulation and biological activities of the autotaxin-LPA axis. Progress in Lipid Research, 46(2), 145–160. https://doi.org/10.1016/j.plipres.2007.02.001.PubMedCrossRef

27.

Yung, Y. C., Stoddard, N. C., & Chun, J. (2014). LPA receptor signaling: pharmacology, physiology, and pathophysiology. Journal of Lipid Research, 55(7), 1192–1214. https://doi.org/10.1194/jlr.R046458.PubMedPubMedCentralCrossRef

28.

Leblanc, R., & Peyruchaud, O. (2015). New insights into the autotaxin/LPA axis in cancer development and metastasis. Experimental Cell Research, 333(2), 183–189. https://doi.org/10.1016/j.yexcr.2014.11.010.PubMedCrossRef

29.

Jonkers, J., & Moolenaar, W. H. (2009). Mammary tumorigenesis through LPA receptor signaling. Cancer Cell, 15(6), 457–459. https://doi.org/10.1016/j.ccr.2009.05.003.PubMedCrossRef

30.

Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., Arestad, A., Cioce, V., Schiffmann, E., & Liotta, L. A. (1992). Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. The Journal of Biological Chemistry, 267(4), 2524–2529.PubMed

31.

Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G. B., Inoue, K., Aoki, J., & Arai, H. (2002). Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology, 158(2), 227–233. https://doi.org/10.1083/jcb.200204026.PubMedPubMedCentralCrossRef

32.

Tokumura, A., Majima, E., Kariya, Y., Tominaga, K., Kogure, K., Yasuda, K., & Fukuzawa, K. (2002). Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. The Journal of Biological Chemistry, 277(42), 39436–39442. https://doi.org/10.1074/jbc.M205623200.PubMedCrossRef

33.

Benesch, M. G. K., Ko, Y. M., McMullen, T. P. W., & Brindley, D. N. (2014). Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions. FEBS Letters, 588(16), 2712–2727. https://doi.org/10.1016/j.febslet.2014.02.009.PubMedCrossRef

34.

Barbayianni, E., Kaffe, E., Aidinis, V., & Kokotos, G. (2015). Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer. Progress in Lipid Research, 58, 76–96. https://doi.org/10.1016/j.plipres.2015.02.001.PubMedCrossRef

35.

Federico, L., Jeong, K. J., Vellano, C. P., & Mills, G. B. (2016). Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. Journal of Lipid Research, 57(1), 25–35. https://doi.org/10.1194/jlr.R060020.PubMedPubMedCentralCrossRef

36.

Kanda, H., Newton, R., Klein, R., Morita, Y., Gunn, M. D., & Rosen, S. D. (2008). Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nature Immunology, 9(4), 415–423. https://doi.org/10.1038/ni1573.PubMedPubMedCentralCrossRef

37.

Nakasaki, T., Tanaka, T., Okudaira, S., Hirosawa, M., Umemoto, E., Otani, K., Jin, S., Bai, Z., Hayasaka, H., Fukui, Y., Aozasa, K., Fujita, N., Tsuruo, T., Ozono, K., Aoki, J., & Miyasaka, M. (2008). Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. The American Journal of Pathology, 173(5), 1566–1576. https://doi.org/10.2353/ajpath.2008.071153.PubMedPubMedCentralCrossRef

38.

Nakamura, K., Ohkawa, R., Okubo, S., Yokota, H., Ikeda, H., Yatomi, Y., et al. (2009). Autotaxin enzyme immunoassay in human cerebrospinal fluid samples. Clinica Chimica Acta, 405(1–2), 160–162. https://doi.org/10.1016/j.cca.2009.04.025.CrossRef

39.

van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., Pettit, T. R., Wakelam, M. J. O., Saulnier-Blache, J. S., Mummery, C. L., Moolenaar, W. H., & Jonkers, J. (2006). Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Molecular and Cellular Biology, 26(13), 5015–5022. https://doi.org/10.1128/Mcb.02419-05.PubMedPubMedCentralCrossRef

40.

Koike, S., Keino-Masu, K., & Masu, M. (2010). Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-rho-ROCK pathway. Biochemical and Biophysical Research Communications, 400(1), 66–71. https://doi.org/10.1016/j.bbrc.2010.08.008.PubMedCrossRef

41.

Moolenaar, W. H., Houben, A. J., Lee, S. J., & van Meeteren, L. A. (2013). Autotaxin in embryonic development. Biochimica et Biophysica Acta, 1831(1), 13–19. https://doi.org/10.1016/j.bbalip.2012.09.013.PubMedCrossRef

42.

Sasagawa, T., Okita, M., Murakami, J., Kato, T., & Watanabe, A. (1999). Abnormal serum lysophospholipids in multiple myeloma patients. Lipids, 34(1), 17–21.PubMedCrossRef

43.

Eder, A. M., Sasagawa, T., Mao, M., Aoki, J., & Mills, G. B. (2000). Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clinical Cancer Research, 6(6), 2482–2491.PubMed

44.

Hu, Y. L., Tee, M. K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., & Jaffe, R. B. (2001). Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. Journal of the National Cancer Institute, 93(10), 762–768.PubMedCrossRef

45.

Li, T. T., Alemayehu, M., Aziziyeh, A. I., Pape, C., Pampillo, M., Postovit, L. M., Mills, G. B., Babwah, A. V., & Bhattacharya, M. (2009). Beta-Arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Molecular Cancer Research, 7(7), 1064–1077. https://doi.org/10.1158/1541-7786.Mcr-08-0578. PubMedCrossRef

46.

Yang, D. Z., Yang, W. H., Zhang, Q., Hu, Y., Bao, L., & Damirin, A. (2013). Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2. Oncology Letters, 5(3), 1048–1052. https://doi.org/10.3892/ol.2013.1107.PubMedPubMedCentralCrossRef

47.

Mahanivong, C., Chen, H. M., Yee, S. W., Pan, Z. K., Dong, Z., & Huang, S. (2008). Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene, 27(9), 1273–1280. https://doi.org/10.1038/sj.onc.1210746.PubMedCrossRef

48.

Fishman, D. A., Liu, Y., Ellerbroek, S. M., & Stack, M. S. (2001). Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Research, 61(7), 3194–3199.PubMed

49.

Yu, S., Murph, M. M., Lu, Y., Liu, S., Hall, H. S., Liu, J., Stephens, C., Fang, X., & Mills, G. B. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. Journal of the National Cancer Institute, 100(22), 1630–1642. https://doi.org/10.1093/jnci/djn378.PubMedPubMedCentralCrossRef

50.

Ishii, I., Fukushima, N., Ye, X. Q., & Chun, J. (2004). Lysophospholipid receptors: signaling and biology. Annual Review of Biochemistry, 73, 321–354. https://doi.org/10.1146/annurev.biochem.73.011303.073731.PubMedCrossRef

51.

An, S. Z., Bleu, T., Hallmark, O. G., & Goetzl, E. J. (1998). Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. The Journal of Biological Chemistry, 273(14), 7906–7910. https://doi.org/10.1074/jbc.273.14.7906.PubMedCrossRef

52.

Sun, K., Duan, X. Y., Cai, H., Liu, X. H., Yang, Y., Li, M., et al. (2016). Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells. Clinical and Experimental Medicine, 16(1), 37–47. https://doi.org/10.1007/s10238-015-0336-7.PubMedCrossRef

53.

Sun, H., Ren, J., Zhu, Q., Kong, F. Z., Wu, L., & Pan, B. R. (2009). Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. World Journal of Gastroenterology, 15(36), 4547–4555.PubMedPubMedCentralCrossRef

54.

Yang, M., Zhong, W. W., Srivastava, N., Slavin, A., Yang, J. X., Hoey, T., et al. (2005). G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the beta-catenin pathway. Proceedings of the National Academy of Sciences of the United States of America, 102(17), 6027–6032. https://doi.org/10.1073/pnas.0501535102.PubMedPubMedCentralCrossRef

55.

Brusevold, I. J., Tveteraas, I. H., Aasrum, M., Odegard, J., Sandnes, D. L., & Christoffersen, T. (2014). Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells. BMC Cancer, 14. https://doi.org/10.1186/1471-2407-14-432.

56.

Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., et al. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. The Journal of Clinical Investigation, 114(12), 1714–1725. https://doi.org/10.1172/JCI22123.PubMedPubMedCentralCrossRef

57.

Taghavi, P., Verhoeven, E., Jacobs, J. J., Lambooij, J. P., Stortelers, C., Tanger, E., et al. (2008). In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene, 27(54), 6806–6816. https://doi.org/10.1038/onc.2008.294.PubMedCrossRef

58.

Kitayama, J., Shida, D., Sako, A., Ishikawa, M., Hama, K., Aoki, J., Arai, H., & Nagawa, H. (2004). Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Research, 6(6), R640–R646. https://doi.org/10.1186/bcr935.PubMedPubMedCentralCrossRef

59.

Lin, S., Wang, D., Iyer, S., Ghaleb, A. M., Shim, H., Yang, V. W., Chun, J., & Yun, C. C. (2009). The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology, 136(5), 1711–1720. https://doi.org/10.1053/j.gastro.2009.01.002.PubMedPubMedCentralCrossRef

60.

Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., Yu, S., Stephens, L. C., Cui, X., Murrow, G., Coombes, K., Muller, W., Hung, M. C., Perou, C. M., Lee, A. V., Fang, X., & Mills, G. B. (2009). Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell, 15(6), 539–550. https://doi.org/10.1016/j.ccr.2009.03.027.PubMedPubMedCentralCrossRef

61.

Seo, E. J., Kwon, Y. W., Jang, I. H., Kim, D. K., Lee, S. I., Choi, E. J., Kim, K. H., Suh, D. S., Lee, J. H., Choi, K. U., Lee, J. W., Mok, H. J., Kim, K. P., Matsumoto, H., Aoki, J., & Kim, J. H. (2016). Autotaxin regulates maintenance of ovarian Cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism. Stem Cells, 34(3), 551–564. https://doi.org/10.1002/stem.2279. PubMedCrossRef

62.

Kawagoe, H., Stracke, M. L., Nakamura, H., & Sano, K. (1997). Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Research, 57(12), 2516–2521.PubMed

63.

Zhang, G., Zhao, Z., Xu, S., Ni, L., & Wang, X. (1999). Expression of autotaxin mRNA in human hepatocellular carcinoma. Chinese Medical Journal, 112(4), 330–332.PubMed

64.

Stassar, M. J., Devitt, G., Brosius, M., Rinnab, L., Prang, J., Schradin, T., et al. (2001). Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. British Journal of Cancer, 85(9), 1372–1382. https://doi.org/10.1054/bjoc.2001.2074.PubMedPubMedCentralCrossRef

65.

Kehlen, A., Englert, N., Seifert, A., Klonisch, T., Dralle, H., Langner, E., et al. (2004). Expression, regulation and function of autotaxin in thyroid carcinomas. International Journal of Cancer, 109(6), 833–838. https://doi.org/10.1002/ijc.20022.PubMedCrossRef

66.

Hoelzinger, D. B., Mariani, L., Weis, J., Woyke, T., Berens, T. J., McDonough, W. S., Sloan, A., Coons, S. W., & Berens, M. E. (2005). Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia, 7(1), 7–16. https://doi.org/10.1593/neo.04535.PubMedPubMedCentralCrossRef

67.

Masuda, A., Nakamura, K., Izutsu, K., Igarashi, K., Ohkawa, R., Jona, M., Higashi, K., Yokota, H., Okudaira, S., Kishimoto, T., Watanabe, T., Koike, Y., Ikeda, H., Kozai, Y., Kurokawa, M., Aoki, J., & Yatomi, Y. (2008). Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. British Journal of Haematology, 143(1), 60–70. https://doi.org/10.1111/j.1365-2141.2008.07325.x.PubMedCrossRef

68.

Nam, S. W., Clair, T., Campo, C. K., Lee, H. Y., Liotta, L. A., & Stracke, M. L. (2000). Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene, 19(2), 241–247. https://doi.org/10.1038/sj.onc.1203263.PubMedCrossRef

69.

Banerjee, S., Norman, D. D., Lee, S. C., Parrill, A. L., Pham, T. C., Baker, D. L., et al. (2017). Highly potent non-carboxylic acid Autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast Cancer stem cells. Journal of Medicinal Chemistry, 60(4), 1309–1324. https://doi.org/10.1021/acs.jmedchem.6b01270.PubMedCrossRef

70.

Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell, 21(3), 309–322. https://doi.org/10.1016/j.ccr.2012.02.022.PubMedCrossRef

71.

Charles, N., Ozawa, T., Squatrito, M., Bleau, A. M., Brennan, C. W., Hambardzumyan, D., & Holland, E. C. (2010). Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell, 6(2), 141–152. https://doi.org/10.1016/j.stem.2010.01.001.PubMedCrossRef

72.

Vermeulen, L., Melo, F. D. S. E., van der Heijden, M., Cameron, K., de Jong, J. H., Borovski, T., et al. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12(5), 468–U121. https://doi.org/10.1038/ncb2048. PubMedCrossRef

73.

Benesch, M. G. K., Yang, Z., Tang, X., Meng, G., & Brindley, D. N. (2017). Lysophosphatidate signaling: the tumor Microenvironment's new nemesis. Trends in Cancer, 3(11), 748–752. https://doi.org/10.1016/j.trecan.2017.09.004.PubMedCrossRef

74.

Benesch, M. G., Zhao, Y. Y., Curtis, J. M., McMullen, T. P., & Brindley, D. N. (2015). Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. Journal of Lipid Research, 56(6), 1134–1144. https://doi.org/10.1194/jlr.M057661.PubMedPubMedCentralCrossRef

75.

Benesch, M. G., Tang, X., Dewald, J., Dong, W. F., Mackey, J. R., Hemmings, D. G., et al. (2015). Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression. The FASEB Journal, 29(9), 3990–4000. https://doi.org/10.1096/fj.15-274480.PubMedCrossRef

76.

Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D. (2008). The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nature Medicine, 14(1), 45–54. https://doi.org/10.1038/nm1685.PubMedCrossRef

77.

Lee, S. C., Fujiwara, Y., & Tigyi, G. J. (2015). Uncovering unique roles of LPA receptors in the tumor microenvironment. Receptors & Clinical Investigation, 2(1). https://doi.org/10.14800/rci.440.

78.

Kanehira, M., Fujiwara, T., Nakajima, S., Okitsu, Y., Onishi, Y., Fukuhara, N., Ichinohasama, R., Okada, Y., & Harigae, H. (2017). An lysophosphatidic acid receptors 1 and 3 Axis governs cellular senescence of mesenchymal stromal cells and promotes growth and vascularization of multiple myeloma. Stem Cells, 35(3), 739–753. https://doi.org/10.1002/stem.2499. PubMedCrossRef

79.

Wu, X. B., Liu, Y., Wang, G. H., Xu, X., Cai, Y., Wang, H. Y., Li, Y. Q., Meng, H. F., Dai, F., & Jin, J. D. (2016). Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-kappa B activation. Scientific Reports, 6. https://doi.org/10.1038/srep21420.

80.

Huang, W. H., Chang, M. C., Tsai, K. S., Hung, M. C., Chen, H. L., & Hung, S. C. (2013). Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene, 32(37), 4343–4354. https://doi.org/10.1038/onc.2012.458.PubMedCrossRef

81.

Jeon, E. S., Moon, H. J., Lee, M. J., Song, H. Y., Kim, Y. M., Cho, M., Suh, D. S., Yoon, M. S., Chang, C. L., Jung, J. S., & Kim, J. H. (2008). Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells, 26(3), 789–797. https://doi.org/10.1634/stemcells.2007-0742.PubMedCrossRef

82.

Jeon, E. S., Heo, S. C., Lee, I. H., Choi, Y. J., Park, J. H., Choi, K. U., Park, D. Y., Suh, D. S., Yoon, M. S., & Kim, J. H. (2010). Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells. Experimental & Molecular Medicine, 42(4), 280–293. https://doi.org/10.3858/emm.2010.42.4.027.CrossRef

83.

Heo, S. C., Lee, K. O., Shin, S. H., Kwon, Y. W., Kim, Y. M., Lee, C. H., Kim, Y. D., Lee, M. K., Yoon, M. S., & Kim, J. H. (2011). Periostin mediates human adipose tissue-derived mesenchymal stem cell-stimulated tumor growth in a xenograft lung adenocarcinoma model. Biochimica et Biophysica Acta, 1813(12), 2061–2070. https://doi.org/10.1016/j.bbamcr.2011.08.004.PubMedCrossRef

84.

Shin, S. H., Kim, J., Heo, S. C., Kwon, Y. W., Kim, Y. M., Kim, I. S., Lee, T. G., & Kim, J. H. (2012). Proteomic identification of Betaig-h3 as a lysophosphatidic acid-induced secreted protein of human mesenchymal stem cells: paracrine activation of A549 lung adenocarcinoma cells by Betaig-h3. Molecular & Cellular Proteomics, 11(2), M111.012385. https://doi.org/10.1074/mcp.M111.012385.CrossRef

85.

Kudo, Y., Siriwardena, B. S., Hatano, H., Ogawa, I., & Takata, T. (2007). Periostin: novel diagnostic and therapeutic target for cancer. Histology and Histopathology, 22(10), 1167–1174. https://doi.org/10.14670/HH-22.1167. PubMedCrossRef

86.

Mosher, D. F., Johansson, M. W., Gillis, M. E., & Annis, D. S. (2015). Periostin and TGF-beta-induced protein: two peas in a pod? Critical Reviews in Biochemistry and Molecular Biology, 50(5), 427–439. https://doi.org/10.3109/10409238.2015.1069791. PubMedPubMedCentralCrossRef

87.

Kim, B. R., Jang, I. H., Shin, S. H., Kwon, Y. W., Heo, S. C., Choi, E. J., Lee, J. S., & Kim, J. H. (2014). Therapeutic angiogenesis in a murine model of limb ischemia by recombinant periostin and its fasciclin I domain. Biochimica et Biophysica Acta, 1842(9), 1324–1332. https://doi.org/10.1016/j.bbadis.2014.05.004.PubMedCrossRef

88.

Kim, B. R., Kwon, Y. W., Park, G. T., Choi, E. J., Seo, J. K., Jang, I. H., Kim, S. C., Ko, H. C., Lee, S. C., & Kim, J. H. (2017). Identification of a novel angiogenic peptide from periostin. PLoS One, 12(11), e0187464. https://doi.org/10.1371/journal.pone.0187464.PubMedPubMedCentralCrossRef

89.

Choi, K. U., Yun, J. S., Lee, I. H., Heo, S. C., Shin, S. H., Jeon, E. S., Choi, Y. J., Suh, D. S., Yoon, M. S., & Kim, J. H. (2011). Lysophosphatidic acid-induced expression of periostin in stromal cells: prognoistic relevance of periostin expression in epithelial ovarian cancer. International Journal of Cancer, 128(2), 332–342. https://doi.org/10.1002/ijc.25341.PubMedCrossRef

90.

Fukushima, N., Kikuchi, Y., Nishiyama, T., Kudo, A., & Fukayama, M. (2008). Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Modern Pathology, 21(8), 1044–1053. https://doi.org/10.1038/modpathol.2008.77.PubMedCrossRef

91.

Kikuchi, Y., Kashima, T. G., Nishiyama, T., Shimazu, K., Morishita, Y., Shimazaki, M., Kii, I., Horie, H., Nagai, H., Kudo, A., & Fukayama, M. (2008). Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. The Journal of Histochemistry and Cytochemistry, 56(8), 753–764. https://doi.org/10.1369/jhc.2008.951061.PubMedPubMedCentralCrossRef

92.

Soltermann, A., Tischler, V., Arbogast, S., Braun, J., Probst-Hensch, N., Weder, W., Moch, H., & Kristiansen, G. (2008). Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clinical Cancer Research, 14(22), 7430–7437. https://doi.org/10.1158/1078-0432.CCR-08-0935.PubMedCrossRef

93.

Bao, S., Ouyang, G., Bai, X., Huang, Z., Ma, C., Liu, M., Shao, R., Anderson, R. M., Rich, J. N., & Wang, X. F. (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell, 5(4), 329–339.PubMedCrossRef

94.

Kudo, Y., Ogawa, I., Kitajima, S., Kitagawa, M., Kawai, H., Gaffney, P. M., Miyauchi, M., & Takata, T. (2006). Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Research, 66(14), 6928–6935. https://doi.org/10.1158/0008-5472.CAN-05-4540.PubMedCrossRef

95.

Shao, R., Bao, S. D., Bai, X. F., Blanchette, C., Anderson, R. M., Dang, T. Y., et al. (2004). Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and Cellular Biology, 24(9), 3992–4003. https://doi.org/10.1128/Mcb.24.9.3992-4003.2004.PubMedPubMedCentralCrossRef

96.

Contie, S., Voorzanger-Rousselot, N., Litvin, J., Clezardin, P., & Garnero, P. (2011). Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. International Journal of Cancer, 128(2), 352–360. https://doi.org/10.1002/ijc.25591.PubMedCrossRef

97.

Malanchi, I., Santamaria-Martinez, A., Susanto, E., Peng, H., Lehr, H. A., Delaloye, J. F., et al. (2012). Interactions between cancer stem cells and their niche govern metastatic colonization. Nature, 481(7379), 85–U95. https://doi.org/10.1038/nature10694. CrossRef

98.

Ptaszynska, M. M., Pendrak, M. L., Stracke, M. L., & Roberts, D. D. (2010). Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Molecular Cancer Research, 8(3), 309–321. https://doi.org/10.1158/1541-7786.MCR-09-0288.PubMedCrossRef

99.

Xu, X., & Prestwich, G. D. (2010). Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer, 116(7), 1739–1750. https://doi.org/10.1002/cncr.24907.PubMedPubMedCentralCrossRef

100.

Boucher, J., Quilliot, D., Praderes, J. P., Simon, M. F., Gres, S., Guigne, C., et al. (2005). Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia, 48(3), 569–577. https://doi.org/10.1007/s00125-004-1660-8.PubMedPubMedCentralCrossRef

101.

Dusaulcy, R., Rancoule, C., Gres, S., Wanecq, E., Colom, A., Guigne, C., et al. (2011). Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. Journal of Lipid Research, 52(6), 1247–1255. https://doi.org/10.1194/jlr.M014985.PubMedPubMedCentralCrossRef

102.

Ferry, G., Tellier, E., Try, A., Gres, S., Naime, I., Simon, M. F., et al. (2003). Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation - up-regulated expression with adipocyte differentiation and obesity. The Journal of Biological Chemistry, 278(20), 18162–18169. https://doi.org/10.1074/jbc.M301158200.PubMedPubMedCentralCrossRef

103.

Nishimura, S., Nagasaki, M., Okudaira, S., Aoki, J., Ohmori, T., Ohkawa, R., Nakamura, K., Igarashi, K., Yamashita, H., Eto, K., Uno, K., Hayashi, N., Kadowaki, T., Komuro, I., Yatomi, Y., & Nagai, R. (2014). ENPP2 contributes to adipose tissue expansion and insulin resistance in diet-induced obesity. Diabetes, 63(12), 4154–4164. https://doi.org/10.2337/db13-1694.PubMedCrossRef

104.

Georas, S. N. (2009). Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity. Immunologic Research, 45(2–3), 229–238. https://doi.org/10.1007/s12026-009-8104-y.PubMedCrossRef

105.

Yamada, T., Sato, K., Komachi, M., Malchinkhuu, E., Tobo, M., Kimura, T., Kuwabara, A., Yanagita, Y., Ikeya, T., Tanahashi, Y., Ogawa, T., Ohwada, S., Morishita, Y., Ohta, H., Im, D. S., Tamoto, K., Tomura, H., & Okajima, F. (2004). Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. The Journal of Biological Chemistry, 279(8), 6595–6605. https://doi.org/10.1074/jbc.M308133200.PubMedCrossRef

106.

Lou, L. Q., Chen, Y. X., Jin, L. Z., Li, X. F., Tao, X. F., Zhu, J. H., et al. (2013). Enhancement of invasion of hepatocellular carcinoma cells through lysophosphatidic acid receptor. The Journal of International Medical Research, 41(1), 55–63. https://doi.org/10.1177/0300060512474124.PubMedCrossRef

107.

North, E. J., Howard, A. L., Wanjala, I. W., Pham, T. C. T., Baker, D. L., & Parrill, A. L. (2010). Pharmacophore development and application toward the identification of novel, small-molecule Autotaxin inhibitors. Journal of Medicinal Chemistry, 53(8), 3095–3105. https://doi.org/10.1021/jm901718z.PubMedCrossRef

108.

Gierse, J., Thorarensen, A., Beltey, K., Bradshaw-Pierce, E., Cortes-Burgos, L., Hall, T., Johnston, A., Murphy, M., Nemirovskiy, O., Ogawa, S., Pegg, L., Pelc, M., Prinsen, M., Schnute, M., Wendling, J., Wene, S., Weinberg, R., Wittwer, A., Zweifel, B., & Masferrer, J. (2010). A novel Autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. The Journal of Pharmacology and Experimental Therapeutics, 334(1), 310–317. https://doi.org/10.1124/jpet.110.165845.PubMedCrossRef

109.

Bhave, S. R., Dadey, D. Y., Karvas, R. M., Ferraro, D. J., Kotipatruni, R. P., Jaboin, J. J., et al. (2013). Autotaxin inhibition with PF-8380 enhances the Radiosensitivity of human and murine glioblastoma cell lines. Frontiers in Oncology, 3, 236. https://doi.org/10.3389/fonc.2013.00236.PubMedPubMedCentralCrossRef

110.

Benesch, M. G., Tang, X., Maeda, T., Ohhata, A., Zhao, Y. Y., Kok, B. P., et al. (2014). Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. The FASEB Journal, 28(6), 2655–2666. https://doi.org/10.1096/fj.13-248641.PubMedCrossRef

111.

Hirane, M., Ishii, S., Tomimatsu, A., Fukushima, K., Takahashi, K., Fukushima, N., Honoki, K., & Tsujiuchi, T. (2016). Different induction of LPA receptors by chemical liver carcinogens regulates cellular functions of liver epithelial WB-F344 cells. Molecular Carcinogenesis, 55(11), 1573–1583. https://doi.org/10.1002/mc.22410.PubMedCrossRef

112.

Zhang, H., Xu, X., Gajewiak, J., Tsukahara, R., Fujiwara, Y., Liu, J., Fells, J. I., Perygin, D., Parrill, A. L., Tigyi, G., & Prestwich, G. D. (2009). Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Research, 69(13), 5441–5449. https://doi.org/10.1158/0008-5472.CAN-09-0302.PubMedPubMedCentralCrossRef

113.

Schleicher, S. M., Thotala, D. K., Linkous, A. G., Hu, R., Leahy, K. M., Yazlovitskaya, E. M., & Hallahan, D. E. (2011). Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS One, 6(7), e22182. https://doi.org/10.1371/journal.pone.0022182.PubMedPubMedCentralCrossRef

Title: Role of autotaxin in cancer stem cells
Authors: Dongjun Lee
Dong-Soo Suh
Sue Chin Lee
Gabor J. Tigyi
Jae Ho Kim
Publication date: 01-09-2018
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9745-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2018

Triumph and tumult of matrix metalloproteinases and their crosstalk with eicosanoids in cancer

Stress, inflammation, and eicosanoids: an emerging perspective

Oxygenated lipid signaling in tumor-associated macrophages—focus on colon cancer

Eicosanoids in prostate cancer

Eicosanoids and HB-EGF/EGFR in cancer

Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer